Gall S A, DiSaia P J, Schmidt H, Mittelstaedt L, Newman P, Creasman W
Am J Obstet Gynecol. 1978 Nov 1;132(5):555-60. doi: 10.1016/0002-9378(78)90752-4.
Manifestations of clinical toxicity were evaluated following 341 courses of intravenous Corynebacterium parvum adjuvant immunotherapy in patients with ovarian and cervical carcinoma. Most patients exhibited symptoms of minor toxicity, which decreased in intensity as subsequent courses of therapy were administered. Temperature elevations to 38.5 degrees C. were the most objectively measured signs of toxicity but temperature elevations greater than 38.5 degrees C. occurred following only 20.5 per cent of the infusions. Blood pressure alterations were not a serious problem and no serious central nervous system or renal toxicity was noted. The minor side effects should not preclude the use of C. parvum as an immunopotentiating agent if it is shown to be beneficial in the treatment of human malignant disease.
在341例卵巢癌和宫颈癌患者接受静脉注射短小棒状杆菌辅助免疫治疗的疗程后,对临床毒性表现进行了评估。大多数患者表现出轻微毒性症状,随着后续治疗疗程的进行,症状强度有所减轻。体温升高至38.5摄氏度是最客观测量到的毒性体征,但仅20.5%的输注后出现体温升高超过38.5摄氏度的情况。血压改变不是严重问题,未观察到严重的中枢神经系统或肾脏毒性。如果短小棒状杆菌在治疗人类恶性疾病中显示出有益效果,那么这些轻微副作用不应妨碍其作为免疫增强剂的使用。